TrialLeukemia & lymphoma2019

Phase 1/2 study of alemtuzumab with dose-adjusted EPOCH in untreated aggressive T and NK cell lymphomas.

Joseph Roswarski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.